Evotec shares tumble 9% as drug discovery segment weakens
NegativeFinancial Markets

Evotec shares tumble 9% as drug discovery segment weakens
Evotec's shares have dropped by 9% following a reported decline in its drug discovery segment. This downturn raises concerns about the company's future performance and its ability to innovate in a competitive market. Investors are closely watching how Evotec will address these challenges and whether it can regain momentum.
— via World Pulse Now AI Editorial System







